EC approves Roche’s Evrysdi for babies under two months with SMA

Betsy Goodfellow | August 30, 2023 | News story | Research and Development European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy 

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to include infants under two months with a clinical diagnosis of spinal muscular atrophy (SMA).

This extended authorisation follows interim data from the ongoing RAINBOWFISH trial assessing the drug for the treatment of pre-symptomatic babies from birth to six weeks with Type 1 SMA. The trial included six babies with two or three copies of the SMN2 gene, who completed at least a year of study assessments, all were able to sit after a year on Evrysdi, four could stand and three could walk independently.

The safety profile of the drug remained consistent with previous data, with the most common adverse reactions being fever, diarrhoea, rash, upper respiratory tract infection (including nasopharyngitis rhinitis), lower respiratory tract infection (including pneumonia, bronchitis), constipation, vomiting and cough.

Dr Nicole Gusset, president and CEO of SMA Europe, commented: “The SMA community welcomes the EC’s decision to extend the use of Evrysdi from birth. Preserving motor neurons from the earliest age possible and preventing their irreversible loss can have a substantial impact on a person’s future ability to move and function. We look forward to continued collaborative efforts to improve diagnosis, including newborn screening, and ensuring all individuals living with SMA have access to medicines.”

Levi Garraway, MD PhD, Roche’s chief medical officer and head of Global Product Development, added: “With this label extension, we can treat babies soon after birth with Evrysdi, allowing them the greatest chance to achieve the milestones of sitting, standing and walking, similar to healthy children.”

The drug was previously approved in the EU in March 2021 for patients over the age of two months.

Betsy Goodfellow

Related Content

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

NMD Pharma has announced that the first patient has been dosed in its phase 2 …

EC approves Menarini Group’s Orserdu for breast cancer treatment

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) …

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the …

Latest content